


In the Claims

Claim 1 (Currently amended): A growth factor binding compound comprising a plurality of peptide loops attached to a calixarene or a (C<sub>8</sub>-C<sub>12</sub>)aryl, ~~wherein the peptide loops may be the same or different with respect to one another, wherein each peptide loop comprises a plurality of peptides, wherein each peptide comprises a plurality of amino acids, and wherein the peptides may be the same or different with respect to one another~~ wherein each peptide loop comprises a tetrapeptide including a negatively charged amino acid, and wherein the plurality of peptides loops form a portion of said growth factor binding compound capable of binding to a growth factor.


Claims 2-3 (Canceled)

Claim 4 (Previously presented): A growth factor binding compound, of the general structure:



wherein R is n-butyl, n-propyl, benzyl, (C<sub>1</sub>-C<sub>12</sub>) alkyl, (C<sub>7</sub>-C<sub>18</sub>) aralkyl, (C<sub>6</sub>-C<sub>18</sub>) aryl, (C<sub>1</sub>-C<sub>12</sub>) alkenyl, (C<sub>7</sub>-C<sub>18</sub>) aralkenyl, or (C<sub>1</sub>-C<sub>12</sub>) alkylether, and X are independently cyclic peptide loops of the general structure:

J:\USFT141X\Amend-Resp\Resp 2.doc\DNB/mv



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each amino acid side chains that define a tetrapeptide, wherein said tetrapeptide is covalently attached at the amino and carboxy termini of said tetrapeptide to a 3-aminomethyl-5-aminobenzamide linking group, and wherein said tetrapeptide is selected from the group consisting of GDFD (SEQ ID NO. 1), GDDD (SEQ ID NO. 2), D-ADGD (SEQ ID NO. 3), GDLD (SEQ ID NO. 4), GDAD (SEQ ID NO. 5), GDGY (SEQ ID NO. 6), ADGD (SEQ ID NO. 7), GDSD (SEQ ID NO. 8), GKGF (SEQ ID NO. 9), GKGK (SEQ ID NO. 10), GDND (SEQ ID NO. 11), PDGD (SEQ ID NO. 12), GDDG (SEQ ID NO. 13), and GDDY (SEQ ID NO. 14).

Claim 5 (Previously presented): The compound of claim 4, in which said growth factor is a platelet derived growth factor, and wherein said tetrapeptide is GDGY (SEQ ID NO. 6).

Claim 6 (Previously presented): A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 7 (Withdrawn): A method of treatment of a subject having a disease comprising excess cellular proliferation, excess angiogenesis, a tumor, or a combination thereof, wherein said

method comprises administering to the subject an effective amount of the growth factor binding compound of claim 1, or a pharmaceutically acceptable salt thereof.

**Claim 8 (Withdrawn):** The method as in claim 7, wherein said tumor expresses elevated amounts of platelet derived growth factor.

**Claim 9 (Withdrawn):** A method for measuring the amount of a growth factor in a sample, comprising:

obtaining a fluid sample suspected of containing a growth factor;  
contacting said sample with a compound of claim 1 that binds said growth factor; and  
detecting the binding of said growth factor to said compound.

**Claim 10 (Withdrawn):** The method of claim 9, wherein said compound is radiolabeled, fluorescently labeled, or both.

**Claim 11 (Withdrawn):** The method as in claim 9, wherein said compound is attached to a surface.

**Claim 12 (Withdrawn):** A method for the delayed release of a growth factor in a patient, comprising administering to said patient a stoichiometric complex of said growth factor and a compound of claim 1.

**Claim 13 (Withdrawn):** A method of treatment of a subject suffering from, or at risk of, restenosis, comprising administering to the subject an effective amount of the growth factor binding compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the effective amount inhibits, prevents or ameliorates restenosis.

**Claim 14 (Withdrawn):** The method of claim 13 wherein the restenosis results from balloon angioplasty, insertion of a vascular stent, or resection of a blood vessel.

Claim 15 (Currently amended): The compound of claim 4 wherein said growth factor is vascular endothelial growth factor and wherein said tetrapeptide is GKGK (SEQ ID NO. 10), GDGY (SEQ ID NO. 6), or functionally related derivatives comprising a tetrapeptide with a G in the first position and a G in the third position thereof.

Claim 16 (Currently amended): The compound of claim 4 wherein said growth factor is acidic fibroblast growth factor and wherein said tetrapeptide is GDDD (SEQ ID NO. 2), GKGK (SEQ ID NO. 10), GDDG (SEQ ID NO. 13), GDGY (SEQ ID NO. 6), or functionally related derivatives comprising a tetrapeptide with a G in the first position thereof.

Claim 17 (Currently amended): The compound of claim 4 wherein said growth factor is insulin-like growth factor-1 and wherein said tetrapeptide is GDDG (SEQ ID NO. 13) or a functionally related derivative comprising a tetrapeptide with a G in the first position and a D in the second position thereof.

Claim 18 (Withdrawn): The method of claim 7, wherein said administering comprises administering the growth factor binding compound of claim 4, or a pharmaceutically acceptable salt thereof, to the subject.


Claim 19 (Withdrawn): The method of claim 7, wherein said administering comprises administering the composition of claim 6 to the subject.

Claim 20 (Withdrawn): The method of claim 13, wherein said administering comprises administering the growth factor binding compound of claim 4, or a pharmaceutically acceptable salt thereof, to the subject.

Claim 21 (Withdrawn): The method of claim 13, wherein said administering comprises administering the composition of claim 6 to the subject.

Claim 22 (Previously presented): A composition comprising the compound of claim 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 23 (Currently amended): The compound of claim 1, wherein each of the peptide loops have the general structure:



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each peptides amino acids.

Claim 24 (New): The growth factor binding compound according to claim 1, wherein one amino acid is an aromatic amino acid.

Claim 25 (New): The growth factor binding compound according to claim 1, wherein the plurality of peptide loops is attached to the calixarene or the (C<sub>8</sub>-C<sub>12</sub>)aryl with a linking unit.

Claim 26 (New): The growth factor binding compound according to claim 25, wherein the linking unit is selected from the group consisting of 3-aminomethylbenzamide, 3-aminophenylacetamide, and 7-aminonaphthyl-1-carboxamide.

7

Docket No. USF-T141X  
Serial No. 09/811,945

**Claim 27 (New):** The growth factor binding compound according to claim 1, wherein the tetrapeptide comprises at least two negatively charged amino acids.

**Claim 28 (New):** The growth factor binding compound according to claim 1, wherein the tetrapeptide comprises at least three negatively charged amino acids.

**Claim 29 (New):** The growth factor binding compound according to claim 1, wherein each peptide loop is different with respect to one another.

**Claim 30 (New):** The growth factor binding compound according to claim 1, wherein the tetrapeptide comprises amino acids that are different with respect to one another.